Alteration of the Immune Response in Bacterial Infection

Study Overview
=================
Brief Summary
-----------------
The pilot study ARIIBO was conducted to analyze changes in immune parameters reported in obese subjects, which had never been the subject of a global study outside of an infectious context, and studied in period septic only sporadically. This study was intended to contribute to a better understanding of the probably adverse impact of obesity on the immune response to bacterial infections, and to describe a specific immunological profile of an infectious excess risk in obese subjects. In terms of infection, obesity is a risk factor due to mechanical and pharmacodynamic variations, but also to the immune system. One of the best studied immunological parameters in obese patients, leptin resistance, is associated with a decrease in innate and adaptive immunity through a modification of the lymphocyte and cytokine profile. It is important to compare the data collected in obese patients infected (first study called ARIIBO), with those of non-obese subjects presenting the same type of infection, which will be included in the study ARIIBACT

Official Title
-----------------
Alteration of the Immune Response in Bacterial Infection

Conditions
-----------------
Infection

Intervention / Treatment
-----------------
* Biological: blood sample


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age between 18 and 80 years BMI 18 to 25 presence of a bacterial infection pneumopathy (documented or probable) acute pyelonephritis / prostatitis skin and soft tissue infection (erysipelas, fasciitis, excluding pressure ulcers) cholecystitis / cholangitis, surgical site infection signed informed consent Exclusion Criteria: patients with documented viral, parasitic or mycotic infections patients with bacterial infection> 4 weeks (eg endocarditis, osteoarticular infections) patients followed in intensive unit care patients with progressive cancerous pathology or malignant hemopathy diagnosed in the previous five years patients with systemic diseases (connective tissue diseases, vasculitis) known immunodepression syndrome (CVID, HIV ...) immunosuppressive therapy in progress until less than one month before inclusion (corticosteroids, DMARDs, biotherapies, hydroxychloroquine)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Interventional arm<br>blood sample before, during and after treatment for infection | Biological: blood sample<br>* blood sample before, during and after infection treatment<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| cytokin analysis (IL-6, IL-10, IL-17, TNFα, IFNγ) | Description of an immunological profile of inflammation using current inflammatory cytokines during sepsis in non-obese subjects in comparison with this same profile in obese subjects | 1 month | 
| adipokin analysis (leptine, adiponectine) | Description of the kinetics of 2 cytokines more speficically involved in obesity (leptine, adipokinine) during sepsis in non-obese subjects in comparison with this same profile in obese subjects | 1 month | 
| leptin polymorphism analysis | Description of the genetic polymorphism of leptine and leptine receptor in non-obese subjects in comparison with this same profile in obese subjects | 1 month |